The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 478.6 |
| Stock-based compensation | 217.9 |
| Charges associated with convertible senior notes | 0 |
| Impairment charges associated with leased properties | 0.7 |
| Depreciation | 26 |
| Accretion of discount on available-for-sale debt securities, net | 12.7 |
| Amortization of acquired intangible assets | 4.1 |
| Changes in fair values of equity investments | -4 |
| Deferred tax assets | 165.4 |
| Non-cash lease expense | 26.8 |
| Other | 0.7 |
| Accounts receivable | 210.5 |
| Inventory | 15.3 |
| Accounts payable and accrued liabilities | 160.2 |
| Income tax assets and liabilities | -18.8 |
| Other assets and liabilities, net | 44.4 |
| Cash flows from operating activities | 782.7 |
| Purchases of available-for-sale debt securities | 1,319.8 |
| Sales and maturities of available-for-sale debt securities | 1,089.4 |
| Purchases of equity investments | 0 |
| Capital expenditures | 34 |
| Cash flows from investing activities | -264.4 |
| Issuances of common stock under benefit plans | 129.4 |
| Repurchases of common stock | 167.7 |
| Payments to settle convertible senior notes | 0 |
| Cash flows from financing activities | -38.3 |
| Effect of exchange rate changes on cash and cash equivalents | 0 |
| Change in cash and cash equivalents and restricted cash | 480 |
| Cash and cash equivalents at beginning of period | 241 |
| Cash and cash equivalents at end of period | 721 |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)